had a significantly higher BMI (33 v 28 kg/m2, p[0.0001) than those within target range. On univariate analysis, higher BMI led to an increased risk of subprophylactic anti-Xa level (OR 1.2, 95% CI 1.1-1.4, p[0.0001). There were no differences in anti-Xa levels based on age, race, VTE history, operative time, or creatinine clearance.
INTRODUCTION AND OBJECTIVES: Radical cystectomy (RC) is associated with significant morbidities and one of the most common issues is postoperative ileus. Alvimopan, an opioid antagonist, is approved to accelerate gastrointestinal recovery in bowel surgeries. While prior studies assessing the benefit of alvimopan for RC patients showed benefit but they were limited due to being institutional studies with small sample sizes. In this study, we evaluated the impact of alvimopan on RC with population-based data, which is generalizable to the larger medical community. We hypothesize that alvimopan shortens length of stay (LOS) and reduces hospital cost in patients undergoing RC.
METHODS: We identified patients who underwent RC for bladder cancer from 2010 to 2015 in the Premier Healthcare Database, a hospital discharge database capturing approximately 20% of all hospitalizations in the United States. To minimize unmeasured confounders, we compared patients who received alvimopan versus those who did not receive alvimopan only in hospitals with an evidence of administering alvimopan. We utilized the hospital chargemaster data and ICD-9 codes to determine patient and hospital characteristics, the primary outcomes of LOS and hospital cost, and the secondary outcomes of major complications (Clavien grades 3-5) and 90-day readmission for ileus.
RESULTS: A total of 1087 patients met inclusion criteria with 511 (47%) patients receiving alvimopan and 576 (53%) who received no alvimopan. Patient characteristics were well balanced between the two arms of the study. Alvimopan was associated with shorter median LOS (-1.21 days, 95% CI: -1.67 to -0.74, p<0.001) and cost savings (-$1,817, 95% CI: -$3,544 to -$90, p[0.039), attributed to reduced room and board costs, which outweighed increased pharmacy costs (Figure) . There were significantly fewer readmissions for ileus among patients receiving alvimopan (OR 0.61, 95% CI: 0.39 to 0.95, p[0.029). There was no difference between two groups regarding postoperative major complications.
CONCLUSIONS: Alvimopan is associated with a shortened LOS, decreased hospital costs, and reduced readmission for ileus among patients undergoing RC. These data suggest that routine use of alvimopan among patients undergoing RC may reduce the burden of bladder cancer on the health care system.
Source of Funding: none

PD66-10 IMPLEMENTATION OF A REDUCED OPIOID UTILIZATION PROTOCOL FOR RADICAL CYSTECTOMY
Daniel Greenberg*, Jessica Kee, Kerri Stevenson, Elizna Van Zyl, Anisia Dugala, Kris Prado, Harcharan Gill, Eila Skinner, Jay Shah, Stanford, CA INTRODUCTION AND OBJECTIVES: Radical cystectomy (RC) is the gold standard treatment for muscle-invasive bladder cancer. This procedure carries significant morbidity, requires 5-10 hospital days to recover, and has a 30% readmission rate after discharge. Following RC, patients are often exposed to a prolonged course of opioid medications for acute pain management. Previous studies have shown that 6% of patients become newly addicted to opioid medications while in the hospital. To address this risk, we implemented a Reduced Opioid Utilization (ROU) protocol aimed to decrease opioid exposure after RC surgery.
METHODS: We identified causes contributing to excess opioid use and designed a multimodal opioid-sparing pain regimen to create the ROU protocol. Interventions were also aimed at educating patients and healthcare providers on the availability and efficacy of non-opioid medications. We prospectively measured opioid use, calculated as morphine equivalent dose (MED), and pain scores for patients who underwent RC for up to 7 months after implementation of the ROU protocol. We retrospectively compared this data to patients who underwent RC during the 7 months prior to the intervention. Opioid-related adverse drug events (ORADEs), recovery milestones, length of stay, and 90-day complication rates were also compared between cohorts.
RESULTS: 104 patients underwent RC during the study period, 54 (52%) of whose postoperative course followed the ROU protocol. There was no significant difference in age, BMI, comorbidities, or history of previous opioid use between ROU and non-ROU RC patients. ROU patients experienced a statistically significant decrease in opioid exposure in the post-anesthesia care unit (14.8AE2.9 MED vs 30.5AE4.4, p<0.01) and during their inpatient postoperative recovery (85.7AE21.0 MED vs 352.6AE34.4 MED, p<0.001). ROU patients also had a statistically significant decrease in the rate of ORADEs (13% vs 54%, p<0.001), time to first bowel movement (3.08AE0.22 days vs 3.78AE0.24 days, p<0.05), and time to tolerance of a regular diet (2.48AE0.20 days vs 3.84AE0.31 days, p<0.001). There was no
